Neuroendocrine gastrointestinal tumors express somatostatin receptors (ssts) in 80%-90% of cases and somatostatin analogs have become increasingly important in the management of these patients. Most of the presently available somatostatin analogs (octreotide, RC-160, and lanreotide) bind to the sst2 and sst5, and in higher doses to sst3 of the ssts 1-5 described.
Introduction
Neuroendocrine gastrointestinal tumors usually present with metastatic inoperable disease and more or less severe hormonal symtoms [1, 2] . A multimodal approach is then warranted and the aims of treatment is to control hormonal symtoms, reduce circulating hormone levels, prevent further tumor growth and possibly also achieve tumor reduction, stop progression of carcinoid heart disease, prolong survival and improve quality of life. Chemotherapy, i.e., combinations with streptozocin, can produce objective responses in endocrine pancreatic tumors (EPT) but is of little benefit in carcinoid tumors [3, 4] . Alpha-interferon (IFN) has been used in both EPTs and carcinoids with responses in 40%-50% of patients [5, 6] . Liver embolizations can produce biochemical and tumoral responses of varying durations [7, 8] . However, very few patients are cured by any of these therapies and hence, there is a need for other therapeutic options.
Somatostatin analogs, octreotide being the first analog available for clinical use, have become increasingly important in the management of these patients. The rationale for the effect of these agents has been elucidated by the demonstration of somatostatin receptors in 80%-90% of tumors by autoradiography [9] and octreotide scintigraphy [10] , the latter method having emerged as a routine diagnostic tool for staging of the patients, and also as a predictive test for sensitivity to treatment with somatostatin analogs [11] . Most of the somatostatin analogs presently available for clinical use (octreotide, lanreotide, RC-160) bind with high affinity to somatostatin receptors sst2 and sst5, and with lower affinity to sst3 [12] , of the ssts 1-5 described [13] [14] [15] [16] .
The beneficial effects of native somatostatin in blocking the carcinoid flush induced by pentagastrin, reducing circulating levels of serotonin and controlling other symtoms associated with the carcinoid syndrome were described byThulin et al. and Frohlich et al. in 1978 [17, 18] .
However, the clinical use of native somatostatin was hampered by its short half life of only two minutes, which necessitated continuous intravenous infusion, and rebound phenomena that occurred after withdrawal of infusion. In 1982, Bauer et al. reported on the synthesis of the long-acting octapeptide analog, octreotide (or SMS 201-995), which retained the four amino acid sequence presumed to be essential for biological activity and was cyclized with a disulfide bridge to impair degra- dation, with a half-life of two hours that could be given subcutaneously two to three times daily [19] .
Octreotide
Since then, octreotide has been widely applied in the clinic and the short-term or acute use of the drug in carcinoid/hormonal crises and perioperative situations, in which octreotide can be given at high doses (50-100 ug/h) intravenously if necessary, has been life-saving in many patients and increased the safety of giving anesthesia, performing surgery and giving chemotherapy immensely in the patients [20, 21] .
Carcinoids
There is, by now, a large number of reports on long-term treament with octreotide in patients with carcinoid tumors and endocrine pancreatic tumors. Kvols et al. reported symtomatic responses in 88% and biochemical responses (>50 reduction in U-5-HIAA) in 72% of 25 patients with carcinoid tumors treated with 150 ug three times a day in 1986 [22] . The median duration of biochemical response was 12 months. Fifteen of the patients in his study had received prior chemotherapy. Already in 1989, Gorden and Maton performed a meta-analysis of the reported cases in the literature [23] . Eighty cases of carcinoid tumors were reported (47 midgut), of which 62 had been treated for 1-18 months with 50-500 ug two to three times a day subcutaneously. Symtoms had improved in 54 of 59 patients (92%, unchanged in five), and a biochemical response, i.e., > 50% of urinary 5-HIAA or other indices of 5-hydroxytryptamine metabolism, had been achieved in 48 of 71 patients (66%), stabilization in 17 of 71 (24%). Reduction of tumor size was noted in 4 of 48 carcinoids (8%), unchanged tumor size in 41 of 48 (85%) and progression in one. This report did not comprehend information about duration of disease from diagnosis to start ofoctreotide, previous treatments or the duration of response to octreotide. However, thirty-one out of 80 patients developed recurrent symtoms and some of them responded to increased doses. This illustrates the loss of therapeutic response or tachyphylaxis, described by Wynick et al. 1989 , which can be circumvented temporarily by a dose increase [24] .
Endocrine pancreatic tumors

Insulinomas
When octreotide (50 ug twice a day) was given preoperatively, it had inconsistent effects on insulin and glucose levels [25] . In some patients possibly because of more profound suppression of GH and glucagon than tumorproduced insulin, the hypoglycemia was worsened. Patients with metastatic insulinomas given octreotide over long-term improved symtomatically and biochemically in 50% of cases [26] . We now know that 50% of insulinomas lack expression of sst2 [27] , thought to predominanly mediate the biochemical response [28] , which explains the abscence of effect in 50% of insulinomas.
Gastrinomas
More than 50 patients with gastrinomas have been treated with doses of 100-1,500 ug/d, most of them short-term. Of these, 90% had a good clinical response with control of gastric hypersecretion, pain and diarrhea. A signifcant drop in serum gastrin and basal acid secretion was obtained [25] . In a long-term study, Ruszniewski et al. could show that also maximal acid output decreased during 9-12 months of treatment, suggesting an antitrophic effect (i.e., reduction of parietal cell mass) of octreotide [29] . The efficacy ofoctreotide in lowering the number of antral G-cells and its effect on long-lasting hypergastrinemia (i.e., ECL cell hyperplasia) are currently being evaluated. However, octreotide has an undefined role in gastrinomas because of the efficient and more convenient peroral proton pump inhibitors. With the recent development of slow release formulations of somatostatin analogs, there may be subgroups of malignant gastrinomas that could benefit from this treatment.
VIP-omas
In patients with VIP-omas not curable by surgery and in whom chemotherapy is only transiently useful, octreotide is now the treatment of choice. Symtomatic improvement occurs in > 80% of patients at doses of 100-450 ug/d. However, in some patients the beneficial effect lasted only a few days requiring increases in dose [25] . Biochemical responses could be noted in about 80% of patients. Symtomatic relief was not always related to the reduction in plasma concentrations of VIP, indicating that octreotide has a direct effect on the gut. In some cases octreo-
response is independent of plasma glucagon concentrations, suggesting a direct effect of octreotide on the skin. Also in glucagonomas, octreotide can change circulating molecular forms of glucagon, indicating inhibition of posttranslational processing of preproglucagon, thereby reducing circulating bioactive glucagon [31] .
Somatostatinomas
A small number of patients with somatostatinomas have been treated with octreotide and they improved symtomatically and biochemically, which correlated with the presence of somatostatin receptors in the tumors evidenced by octreotide scintigraphy [32] .
The effect on tumor growth in EPT treated with standard doses of octreotide was reported by Maton in his meta-analysis although the degree or percentage of regression (e.g., 50%) was not indicated [25] . Regression was obtained in 8 of 46 patients (17%), no change in 18 6 of 46 (39%) and progression in 20 of 46 (44%). For both tumor markers a statistically signifcant fall was observed after one month, the lowest ratio was seen at three months (P < 0.001) and then it slowly increased indicating tachyphylaxis.
tide has been shown to change the molecular form of circulating VIP possibly into a less bioactive form [30] .
Glucagonomas
In about 90% of patients with glucagonomas who presented a rash when treatment was initiated, octreotide cleared it in a few days. Other symtoms in the syndrome, such as weight loss and diarrhea can improve but octreotide has varying effects on the diabetes. Plasma glucagon were reduced in 60% of patients [25] . The symtomatic
Meta-analysis of dose titration data
Harris and Redfern performed a meta-analysis of data compiled from 62 published studies to examine the relationship between octreotide dose and efficacy in decreasing urinary 5-HIAA, flushing and diarrhea and denned dosing recommendation for maximum therapeutic benefit [33] . Six dose ranges of octreotide were assessed from 100-3,000 ug/d. Patients had to show a reduction in diarrhea, flushing, or 5-HIAA levels of greater than 50% to be included. Reduced U-5-HIAA tended to maximize as the daily octreotide dose increased and maximum response in U-5-HIAA tended to occur over the octreotide dose range of 300-375 ug/d. Increasing doses of octreotide were associated with symtom improvement: a reduction in diarrhea occurred over the dose ranges 100-1000 ug/d, with no additional benefit seen with doses over 1000 ug/d, and octreotide dose ranges from 100 to 2000-3000 ug/d resulted in resolution of flush. So they concluded, that symtom relief and reduced U-5-HIAA levels occurred in a greater percentage with increasing doses. Since the response to octreotide varies markedly among individual patients -possibly attributable to patient-to-patient variations in the relative abundance of high-and low-affinity somatostatin receptors expressed on the tumor cell membrane -it is important to titrate the dose of octreotide in each patient until adequate symtom and biochemical control is achieved.
Antiproliferative effects
The antiproliferative effect of standard doses of octreotide was further studied by two groups (Saltz et three times a day first when tumor progression (> 25% over two to four months) was documented. They achieved CT-verified stabilization in 50% of patients with a median duration of five months. In a German multicentre study, 52 patients with CT-documented tumor progression were treated with octreotide 200 ug three times a day. A stabilization of tumor growth was achieved in 19 of 52 (36.5%) with a median duration of 18 months. Even though reduction in tumor size is rarely seen with standard octreotide treatment of neuroendocrine tumors, these results suggest that octreotide has an antiproliferative effect.
Summary of standard octreotide treatment
Summarizing results reported in the literature up till now [21-26, 30-32, 34-43] , treatment of patients with neuroendocrine gastrointestinal tumors with subcutaneous injections of standard doses of octreotide produces symtomatic or subjective responses in 30%-75% of patients and the response rate appears to dose dependent. Biochemical responses are achieved in 30%-60% of patients and according to Harris' analysis, biochemical responses are also dose dependent, i.e., the dose should be titrated for each patient. More than 50% reduction in tumor size occurs only in 10%-15%, but stabilization can be achieved in 35%-50% of patients. Whether the antitumoral response is dose dependent or not will be discussed. Several in vitro studies indicate that the antiproliferative effect is dose-related [44, 45] . Both the biochemical and the antiproliferative effect of octreotide are considered to be mediated by sst2, the latter via stimulation of tyrosine phosphatase. Octreotide also binds to sst5, which mediates an antitumor response through a different mechanism, probably via calcium fluxes [46] . Occasionally, tumor growth may continue despite ongoing anti-secretory effects, suggesting these actions may be mediated by distinct mechanisms. Since sst2 mediates both biochemical and antiproliferative effects of octreotide, it is important to perform octreotide scintigraphy and possibly also assessment of the sst2 receptor status as predictive tests before initiation of treatment.
Several direct or indirect mechanisms of growth inhibitory activity of octreotide and analogs have been suggested [27] : 1) suppression of the release of trophic hormones (e.g., GH, insulin, prolactin, gut peptides), 2) direct or indirect inhibition of growth factors (e.g., EGF, PDGF), 3) inhibition of angiogenesis, 4) modulation of immunological activity, and 5) direct antimitotic effects via somatostatin receptors on tumor cells.
Adverse effects
The adverse effects of standard octreotide treatment have been rather mild due to the adaptation of normal pituitary and gastrointestinal functions to the drug. Apart from nausea, transient abdominal cramps, flatulence, diarrhea and local reaction at the injection site, no important side effects have been observed. Most sideeffects resolve with time. Octreotide also causes a shortterm inhibition and/or delay of insulin release in response to meals, but this is only accompanied by a slight decrease in glucose tolerance in some patients, without notable changes in glycosylated hemoglobin (HbA lc ). In 20%-50% of patients gallstones are formed de novo, but these remain virtually always asymtomatic [47] . More rare adverse events include hypocalcemia, bradycardia, acute pancreatitis and transitory ischemic attacks (the latter with high-dose in a predisposed patient).
Tachyphylaxis
The median duration of response to standard octreotide treatment is 12 months. Loss of therapeutic response during chronic octreotide therapy is a well-recognised phenomenon [24] . It generally conforms to one or two patterns, both of which have been ascribed altered receptor function: early (down-regulation of ssts, restorable by drug-free interval) and eventual escape (development of receptor-negative clones?). The mechanism for tachyphylaxis is not known. It does not occur, when acromegalic patients are treated with octreotide [48] , so there is a fundamental tumor biological difference between these two diseases, which remains to be elucidated.
High-dose treatment
Very few studies have addressed the potential value of high-dose somatostatin analog treatment in neuroendocrine gastrointestinal tumors. It should be interesting, since a dose-related tumor response has been demonstrated in a variety of tumor models. So far three studies have been reported. In a study performed by our group in 1992-1993, we treated 19 patients with advanced neuroendocrine Gl-tumors (13 carcinoids and six EPT) with a mean duration of disease of 56.7 months and 19 months, respectively, all except four heavily pretreated, nine failing on standard doses of octreotide [49] . Octreotide scintigraphy was positive in 17 of 18 patients before initiation of lanreotide in escalating doses up to 12 mg/d, a dose, which was maintained for one year or until progression. Biochemical responses were achieved in 11 of 19 patients (58%). One patient (5%) showed a partial tumor response, whereas stabilization was obtained in 12 of 19 (70%). We made an interesting observation in tumor biopsies from the patients. Patients with a biochemical response and stable tumor disease showed an increase in the number of apoptotic cells in the tumors with time (six and 12 months) [50] and we suggest that high-dose lanreotide may have induced apoptosis by binding to sst3 as has recently been described [51] . We also made an interesting observation using in vivo PET: in two biochemically responding patients, the uptake of the tracer L-DOPA increased, indicating inhibition of exocytosis (more than synthesis) of peptides and amines by high-dose somatostatin analogs [52] . The frequency of gallstones in this study was 1 of 19 (5%).
Anthony et al. treated 13 patients refractory to standard doses of octreotide with octreotide 6 mg/d and achieved a partial tumor response in 4 of 13 (31%) and a stabilization in 2 of 13 (15%) [53] . In the same report high-dose lanreotide (9 mg/d) was given to 13 patients with mixed diagnoses, e.g., SCLC. Among six midgut carcinoid, three obtained a partial tumor response. Faiss et al. treated 30 patients with metastatic neuroendocrine Gl-tumors with 15 mg/d lanreotide for one year [54] . One complete and one partial tumor response was achieved. So, it appears that high-dose octreotide/lanreotide can produce additional antiproliferative effects in patients failing on standard doses of octreotide.
Continuous infusion
Several studies in acromegaly have indicated that continuous infusion of octreotide has advantages over intermittent subcutaneous injections; one can achieve a more pronounced control of growth hormone (GH) and insulin-like growth factors (IGF-1) levels, clinical and biochemical control can be achieved at lower doses and the adverse effects may be less [55] . To explore this, we perfomed a European multicentre trial treating 35 patients with the carcinoid syndrome (19 had failed standard doses of octreotide) with RC-160 at a dose 1.5 mg/d given as a continuous subcutaneous infusion via micropump for three to six months [56] . This is the first clinical study, in which RC-160 has been used and it was of particular interest, since in vitro studies have suggested that RC-160 has a stronger antiproliferative effect than both octreotide and lanreotide [57] . In brief, subjective improvement occurred in about 60%, the biochemical response rate was rather low, only 23% and there was no tumor response but stabilization was achieved in 60% in these advanced cases, which might be considered a response. The frequency of gallstones was 8%. However, the most striking observation in this study was the absence of side-effects: there were no gastrointestinal side-effects with the exception of gallstones, so the treatment was very well tolerated.
Slow release formulations
One of the most important improvements in somatostatin analog treatment is the development of slow release formulations, which relieves the patients of the inconvenience of taking multiple daily injections. Available for clinical use are now Sandostatin-LAR and lanreotide-PR, in which octreotide and lanreotide have been incorporated into microspheres of the biodegradable polymer poly (LD-lactide-coglycolide glucose), which can be given every fourth and second week, respectively. There are already reports about the beneficial value of these formulations in acromegaly and Sandostatin-LAR is expected to become the treatment of choice in acromegaly [58] .
There are three reports on the use of lanreotide-PR in neuroendocrine gastrointestinal tumors. Ruszniewski et al. treated 39 patients with carcinoids with lanreotide-PR 30 mg i.m. every two weeks [59] . They found subjective responses in about 55%, biochemical responses in 42% but no tumor response after six months of treatment. The frequency of gallstones was 5 %. Somewhat higher subjective (73%) and biochemical (55%) response rates were obtained in a German study including eleven patients [60] . Our group participated in a European multicentre study together with centres in Finland, Norway, The Netherlands and Belgium and treated 55 patients (48 carcinoids and seven EPT) with lanreotide-PR 30 mg i.m. every two weeks for six months [61] . Symtomatic improvement was observed in 38% of carcinoids, 67% of gastrinomas and 1 VIP-oma. Biochemical responses were obtained in 47% and tumor responses in two patients (7%), stabilization of tumor growth was achieved in 80%. Side effects were pain and flatulence the first days two to three days after intramuscular injection. The frequency of gallstones was rather high 8 of 30 (27%). During this trial quality of life was studied using a validated EORTC instrument (C30) and assessment after 1 month showed improvements of emotional and cognitive function, global health as well as sleeping disorders and diarrhea. This is the first study that can show that a long-acting somatostatin analog improves quality of life, which is very important since the treatment is palliative.
Combination of IFN plus octreotide
The combination of somatostatin analogs with other drug is also an interesting area for the future. We have already shown that the combination of octreotide plus IFN produces a higher biochemical response rate than either drug alone in carcinoid tumors [62] , we have similar indications in endocrine pancreatic tumors in our institution and a German study will soon disclose whether the combination is better than any of the single drugs in a randomised study. In vitro studies from our group indicate that the combination has a stronger antiproliferative effect than IFN or octreotide alone [50] .
Conclusion
In summary, somatostatin analogs can relieve symtoms, reduce circulating hormone levels and stabilize tumor growth in > 50% of patients. Whether somatostatin analogs can stop the progression of carcinoid heart disease is not known but we are currently looking at it and our general impression is that we have less problems with cardiac disease now than 10-15 years ago. There is no published study that can prove that somatostatin analogs improve survival as yet. The age at diagnosis has not been reduced despite improved diagnostic methods because of the rarity of the disease, so the better survival rates that appear in reports published recently compared to historical controls should reflect improvement in therapeutic procedures. Moreover, the majority of centres working with these patients use a multimodal approach so it is very unlikely that a patient will receive a somatostatin analog as the only treatment during the clinical course of the disease, and hence, it will be very difficult to say that this individual treatment produced a better survival. The important fact is that survival rates are improving and that as we have shown the quality of life is also improved, which is very important for a palliative treatment.
Future perspectives
The future in the area of somatostatin analogs is promising. It is important 1) to explore the clinical usefulness of slow release formulations, possibly also high-dose slow release formulations, 2) to further investigate the potential value of high-dose analog treatment and the possible induction of apoptosis, 3) to study the combination of somatostatin analogs with other drugs (IFN, chemotherapy). 4) Furthermore, somatostatin analogs can be coupled to chemotherapeutic drugs based on the observation of internalization, and the most promising field is 5) receptor subtype-specific analogs and combinations of them. There are already interesting in vitro data in pituitary tumors treated with combinations of subtype-selective analogs indicating additive or synergistic effects of combinations [63] .
In the future, therapy with somatostatin analogs should be based on the sst-status of the tumors in addition to other clinical and tumor biological parameters of the patients to tailor-make treatment for each patient to possibly achieve higher symtomatic and biochemical response rates and more pronounced antiproliferative effects.
